Life Sciences Lab Vacancy Reaches Record Highs in 2026
Biotech hubs face a growing inventory surplus as venture capital investment cooling impacts major research markets.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you feel the local economy in your area is currently getting better or worse?
The U.S. life sciences sector faces significant real estate surpluses as of Q3 2026, with vacancy rates in major hubs like Boston, the Bay Area, and San Diego reaching between 23.8% and 28.5%. These record vacancy levels coincide with a broader downturn in venture capital investment across these key research markets.
Why it matters
High vacancy rates indicate a cooling in the life sciences property market, likely resulting from the recent misalignment between aggressive facility expansion and the slower pace of current venture capital funding. This surplus could impact future infrastructure development plans and lease leverage for biotech tenants.
Greater Boston recorded a 28.1% vacancy rate across its 44.4 million square-foot inventory, while San Diego saw 28.5% vacancy and the Bay Area reached 23.8% vacancy. These figures reflect a period of supply growth paired with tightening capital inflows.
The players
Gillette
A global consumer goods conglomerate that recently acquired the 232 A Street facility in Boston for $99.3 million.
Sanofi
A multinational pharmaceutical firm that has signed lease agreements within the Cambridge life sciences hub.
Revolution Medicines
A clinical-stage oncology company that has secured lab space leases in the Redwood City market.
Exagen
A diagnostics developer that has executed lease agreements for facilities within the Carlsbad area.
The details
Real estate developers completed projects throughout Q3 2026 even as market demand fluctuated, leading to the current surplus of specialized laboratory square footage. Tenants have signed varied lease agreements, such as those in Cambridge, Redwood City, and Carlsbad, but these signings have not absorbed the total available supply. The industry continues to navigate a landscape where construction timelines often exceed the pace of recent venture capital cycles.
Timeline
Q3 2026 marked the primary reporting period for life sciences real estate vacancy data.
Q1-Q3 2026 represented the window for venture capital funding reporting.
The Tech Race
The current venture capital decline marks a significant departure from the 2025 National Institutes of Health funding baseline that previously supported rapid lab growth. This shift forces a reckoning between the existing infrastructure build-out and the cooling pace of capital investment.
Biotech firms seeking new laboratory space now have increased leverage in negotiations due to high vacancy rates in major hubs. However, developers and investors may face stalled project timelines as the current market recalibrates against lower funding levels.
The takeaway
The sector is currently defined by an oversupply of laboratory space relative to the current pace of venture capital investment. Industry observers should monitor Q4 2026 absorption rates to see if these high vacancy percentages begin to stabilize or continue to climb.
Further reading
For broader trends in research infrastructure, see our Biotech coverage.
Source note: This article includes information reported by Commercial Observer.
Live Poll
Do you feel the local economy in your area is currently getting better or worse?
